0001104659-19-036506.txt : 20190619 0001104659-19-036506.hdr.sgml : 20190619 20190619213929 ACCESSION NUMBER: 0001104659-19-036506 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190617 FILED AS OF DATE: 20190619 DATE AS OF CHANGE: 20190619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CARPENTER CHRISTOPHER L. CENTRAL INDEX KEY: 0001746845 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38586 FILM NUMBER: 19907359 MAIL ADDRESS: STREET 1: C/O RUBIUS THERAPEUTICS STREET 2: 325 VASSAR ST., SUITE 1A CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 a4.xml 4 X0306 4 2019-06-17 0 0001709401 Rubius Therapeutics, Inc. RUBY 0001746845 CARPENTER CHRISTOPHER L. C/O RUBIUS THERAPEUTICS, INC. 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common Stock 2019-06-17 4 M 0 18500 2.87 A 53343 D Common Stock 2019-06-17 4 S 0 18500 14.1010 D 34843 D Common Stock 2019-06-18 4 M 0 10858 2.87 A 45701 D Common Stock 2019-06-18 4 S 0 10858 14.2713 D 34843 D Common Stock 2019-06-19 4 M 0 18399 2.87 A 53242 D Common Stock 2019-06-19 4 S 0 18399 13.7979 D 34843 D Stock Option (Right to Buy) 2.87 2019-06-17 4 M 0 18500 0 D 2027-10-24 Common Stock 18500 648657 D Stock Option (Right to Buy) 2.87 2019-06-18 4 M 0 10858 0 D 2027-10-24 Common Stock 10858 637799 D Stock Option (Right to Buy) 2.87 2019-06-19 4 M 0 18399 0 D 2027-10-24 Common Stock 18399 619400 D The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.42, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.11 to $14.56, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.68 to $14.21, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of this option shall vest on September 18, 2018, then in 12 equal quarterly installments thereafter. /s/ Joanne M. Protano, Attorney-in-Fact 2019-06-19